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Background: TP53mutation is associated with decreased survival rate in head and neck squamous cell carcinoma
(HNSCC) patients. We set out to identify microRNAs (miRNAs) whose expression associates with TP53mutation and
survival in HNSCC.
Patients and methods:We analyzed TP53 status by direct sequencing of exons 2 through 11 of a prospective series
of 121 HNSCC samples and assessed its association with outcome in 109 followed-up patients. We carried out miRNA
expression proﬁling on 121 HNSCC samples and 66 normal counterparts. miRNA associations with TP53mutations and
outcome were evaluated.
Results: A TP53mutation was present in 58% of the tumors and TP53mutations were signiﬁcantly associated with a
shorter recurrence-free survival. This association was stronger in the clinical subgroup of patients subjected to adjuvant
therapy after surgery.The expression of 49 miRNAs was signiﬁcantly associated with TP53 status. Among these 49, we
identiﬁed a group of 12 miRNAs whose expression correlates with recurrence-free survival and a group of 4 miRNAs that
correlates with cancer-speciﬁc survival. The two groups share three miRNAs. Importantly, miRNAs that correlate with
survival are independent prognostic factors either when considered individually or as signatures.
Conclusions:miRNAs expression associates with TP53 status and with reduced survival after surgical treatment of
squamous cell carcinoma of the head and neck.
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introduction
Head and neck squamous cell carcinomas (HNSCCs) comprise
5.5% of all incidence of cancers and represent the sixth leading
cancer worldwide with ∼600 000 cases reported annually. Local
recurrence affects about 60% of patients and metastases develop
in 15%–20% of cases [1]. Advances in the surgical and medical
treatments for HNSCC over the past two decades have not
improved overall disease outcomes [2].
TP53 is the most frequent target of genetic alterations in
human cancers, with a prevalence of 20%–80% in HNSCC [3]
(http://www-p53.iarc.fr). The majority of TP53mutations
resides in the exons 5–8, and they are missense mutations
[4], some of which have been reported to have gain-of-function
properties, thereby positively contributing to cancer progression
[5–7]. A number of studies reported that TP53mutations are
generally associated with shorter recurrence-free and/or overall
survival in HNSCC [8–15].
MicroRNAs (miRNAs) are 22 nucleotides-long double
stranded small RNAs, able to modulate gene expression at post-
transcriptional level. According to several studies miRNAs
expression proﬁle is emerging among the best markers for
diagnosis, staging and treatment of cancer, including HNSCC
[16, 17]. A correlation between the expression of speciﬁc
miRNAs, such as miR-375 and -210, and outcome of HNSCC
patients was indeed reported [18, 19].
Several studies have demonstrated the implication of wild-
type p53 in the regulation of maturation and expression of†These two authors contributed equally to this work.
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Figure 1. TP53 status correlates with recurrence-free survival. (A) Pie chart representing the distribution of the different TP53 mutation types identiﬁed in
121 HNSCC patients. (B) Kaplan–Meier analysis showing the correlation between TP53 status and recurrence-free survival in 109 HNSCC patients. (C and D)
On the left, Kaplan–Meier analyses showing the correlation between TP53 status and recurrence-free survival in the clinical subgroups of HNSCC patients
subjected (C) or not (D) to adjuvant treatment with radiation or chemoradiation therapy after the surgery. On the right, Pie chart representing the frequency of
TP53 mutations and the distribution of primary tumor sites in two clinical subgroups subjected or not to adjuvant therapy.
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miRNAs in cancer [20], and we recently reported that also
mutant p53 controls the expression of miRNAs, such as miR-
128-2 and miR-223 [21, 22]. Moreover, miRNAs were recently
found differentially expressed between wild-type and mutant
p53 breast tumors [23].
Here, we report that TP53mutations are associated with
shorter recurrence-free survival in a cohort of 109 HNSCC
patients, as expected. We identiﬁed 49 miRNAs whose
expression discriminates tumors with wild-type from those with
mutated TP53 gene. In particular, 44 and 5 miRNAs are,
respectively, up- and down-regulated in the TP53-mutated
group compared with the wild-type group. Moreover, we
assessed that 12 and 4 of the 49 TP53-associated miRNAs, are
able to predict, respectively, recurrence-free survival and cancer-
speciﬁc survival, independently from other clinical variables,
either individually or as groups.
materials andmethods
study population and clinical samples
The study, approved by the scientiﬁc ethic committee of the Italian National
Cancer Institute ‘Regina Elena’ (Rome) (protocol CE/379/08), involved 123
prospectively enrolled patients with histologically conﬁrmed primary
HNSCC undergoing curative treatment at the Otolaryngology Head and
Neck Surgery Department. Only patients who did not receive any anticancer
therapy before surgery were included in the study. Only HNSCC patients
who developed local recurrence after 1 month from the surgery and with a
follow-up ≥12 months were considered for the prognostic study.
TP53 mutational analysis
See supplementary material, available at Annals of Oncology online.
RNA extraction, labeling and microRNAmicroarray
hybridization and analysis
See supplementary material, available at Annals of Oncology online.
statistical methods
The association between categorical variables was tested by the Pearson χ2
test, χ2 test for trend or Fisher Exact tests, when appropriate.
The hazard risk was estimated for each variable using the Cox univariate
model. A multivariable Cox proportional hazard model was also developed
using stepwise regression (forward selection), enter limit and remove limit
were P = 0.10 and P = 0.15, respectively. Survival curves were calculated by
the Kaplan–Meier product-limit, the log-rank test was used to assess
differences between subgroups. Signiﬁcance was deﬁned at the P < 0.05 level.
The Odds Ratio was estimated for each variable. The SPSS (version 18.0,
SPSS Institute, Chicago, IL) statistical software was used for all analyses.
results
TP53 mutation predicts development of local
recurrence in HNSCC
Demographic and clinical characteristics of the HNSCC patients
included in the study are reported in supplementary Material
and Table S1, available at Annals of Oncology online. The
incidence of TP53mutation in the HNSCC cohort was
determined by direct sequencing of TP53 exons 2 through 11.
Seventy of 121 patients (58%) presented single or multiple TP53
mutations in the tumor tissue (Figure 1A and supplementary
Table S1, available at Annals of Oncology online). Only one
normal tissue counterpart had a TP53 mutation and was not
included in subsequent analyses. We identiﬁed only ﬁve HPV-
positive cases (supplementary Material and Table S1, available
at Annals of Oncology online).
Many studies have shown that TP53 gene mutations are
associated with an increased risk for loco-regional recurrence
and poor outcome [24]. In our HNSCC series, TP53mutation
was associated with a higher probability to develop local
recurrence after diagnosis (Figure 1B). In multivariable Cox
proportional hazards regression model, TP53mutation, as well
as primary tumor site in the pharynx and adjuvant therapy,
result as independent negative prognostic factors for RFS
(Table 1). Primary tumor site and adjuvant therapy were also
prognostic factors for CSS (Table 1).
As TP53-mutated proteins have been extensively
characterized for their ability to confer chemo- and radio-
resistance to cancer cells, including HNSCC cells [13, 25], we
examined the association of TP53mutation with RFS in the two
clinical subgroups of patients subjected or not to adjuvant
therapy. Interestingly, we observed by Kaplan–Meier analysis
that TP53mutation, despite occurring with similar frequency in
the two subgroups (Figure 1C and D, right), was signiﬁcantly
associated with lower RFS, compared with wild-type TP53, only
in HNSCC patients subjected to adjuvant therapy after surgery
(Figure 1C) and not in patients who did not receive adjuvant
therapy (Figure 1D). Of note, the distribution of primary tumor
sites was similar in the two analyzed subgroups (Figure 1C and
D, right). In multivariable analysis, TP53mutation (HR 2.42, CI
Table 1. Results of multivariable analysis of prognostic factors
Factors Recurrence-free survival Cancer-speciﬁc survival
HR (95% CI) P HR (95% CI) P
Primary tumor site
Pharynx versus larynx and oral cavity 3.58 (1.69–7.57) 0.001 4.49 (2.17–9.29) <0.0001
Adjuvant therapy
Yes versus no 2.09 (0.97–4.50) 0.06 4.03 (1.63–10.0) 0.003
TP53 status
mut versus wt 1.92 (0.94–3.94) 0.07 / /
P < 0.1 was considered signiﬁcant.
Mut, mutant; wt, wild type; HR, hazard risk; CI, conﬁdence interval; / = not evaluable.
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Figure 2. microRNAs are differentially expressed between TP53 wild-type and mutated HNSCC samples. (A) Heatmap relative to the unsupervised clustering
analysis of the best 11 of 49 miRNAs distinguishing TP53-mutated and wild-type tumors. (B) Heatmap relative to the semi-unsupervised clustering analysis
representing the deregulation of 49 TP53-related miRNAs in TP53-mutated tumors versus normal samples. (C) Validation of two representative TP53-related
miRNAs (miR-7-5p and miR-370, up- and down- regulated, respectively, in the mutant TP53 group) was carried out by RT-qPCR in a subgroup of HNSCC
patients. Comparison of miRNAs expression between TP53-mutated and wild-type tumors is shown in the left plots. Comparisons of miRNAs expression in tumor
versus normal samples, in the subsets of TP53-mutated tumors (middle plot) and TP53-wt tumors (right plot), are also shown. wt, wild type; mut. mutation.
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1.01–5.78, P = 0.047) and site (HR 3.13, CI 1.28–7.62, P = 0.01)
remained independent prognostic factors for recurrence-free
survival in the group of patients who received adjuvant therapy.
TP53 mutation associates with the expression of
speciﬁc microRNAs in HNSCC
miRNAs expression proﬁling was carried out for 121 HNSCC
samples and 66 normal counterparts. After ﬁltering miRNAs
that were expressed at very low levels or not expressed in most
of the cohort, 209 miRNAs were considered for further analysis.
We evaluated whether the expression levels of miRNAs in
tumor tissues were different by the presence or absence of TP53
mutations. Considering the whole tumor series, we found 49
miRNAs that were able to distinguish wild-type from mutated
TP53-carrying tumors (supplementary Table S2, available at
Annals of Oncology online). A subgroup of the 49 TP53-related
miRNAs was also associated with other clinical variables; we
then conﬁrmed the associations miR-TP53 by constructing
multivariable regression models adjusting for these potentially
confounding clinical variables (supplementary Table S2,
available at Annals of Oncology online).
In particular, we found 44 miRNAs that were up- and 5
miRNAs that were down-regulated in the TP53-mutated group
compared with the wild-type group (supplementary Table S2,
available at Annals of Oncology online); all except one of these
miRNAs were also respectively up- and down-regulated in the
tumor tissues compared with normal tissues, speciﬁcally in the
TP53-mutated group (supplementary Table S3, available at
Annals of Oncology online). On the contrary, only 10 of these 49
miRNAs were signiﬁcantly altered in tumor versus normal
tissues in the wild-type TP53 group and also showed lower
statistical signiﬁcance (supplementary Table S3, available at
Annals of Oncology online).
Heatmaps obtained from the unsupervised clustering of the
11 miRNAs with best performance in distinguishing groups
with mutated and wild-type TP53 (Figure 2A) and from the
semi-unsupervised clustering of the 49 TP53-related miRNAs
distinguishing tumor and normal samples (Figure 2B) are
shown.
We validated by RT-qPCR the up- and down-regulation of,
respectively, miR-7-5p and miR-370, in tumors with mutated
TP53 versus tumors with wild-type TP53 (Figure 2C, left). We
also conﬁrmed that these miRNAs are modulated between
tumor and normal tissues speciﬁcally in the group of tumors
with mutated TP53 (Figure 2C, middle), while no signiﬁcant
changes in expression are observed in patients with wild-type
TP53 (Figure 2C, right).
expression of TP53 mutation-related microRNAs
associates with survival in HNSCC
We next evaluated if the expression of the 49 TP53-associated
miRNAs predicts clinical outcome. We observed, through
Kaplan–Meier analysis, that the expression of 12 miRNAs (e.g.
miR-17-3p, miR-18b-5p, miR-324-5p, miR-19a-3p, miR-200a-
3p, miR-331-3p, miR-21-3p, miR-21-5p, miR-205-5p, miR-151a-
3p, miR-96-5p and miR-429) was associated with shorter RFS
(Table 2), while the expression of 4 miRNAs (e.g. miR-17-3p,
miR-21-3p, miR-21-5p and miR-139-3p) was associated with
shorter CSS (Table 2). Three of such miRNAs (e.g. miR-17-3p,
miR-21-3p, miR-21-5p) associated with both RFS and CSS.
Table 2. Results of Kaplan–Meier
microRNA KM analysisa t-Testa Multivariable analysisa
Log-rank P P HR (95% CI) P
Recurrence-free survival
‘hsa-miR-205-5p’ 0.003 1.05E−14 4.98 (1.67–14.9) 0.004
‘hsa-miR-429’ 0.007 1.69E−21 4.45 (1.59–12.45) 0.004
‘hsa-miR-21-3p’ 0.007 3.50E−17 3.12 (1.28–7.6) 0.01
‘hsa-miR-331-3p’ 0.008 2.49E−22 3.45 (1.24–9.64) 0.01
‘hsa-miR-200a-3p’ 0.039 1.45E−18 3.1 (1.18–7.9) 0.02
‘hsa-miR-19a-3p’ 0.055 2.89E−22 2.86 (1.1–7.7) 0.03
‘hsa-miR-21-5p’ 0.055 1.86E−18 2.77 (1.04–7.38) 0.04
‘hsa-miR-151a-3p’ 0.03 2.01E−30 3 (1–8.97) 0.04
‘hsa-miR-17-3p’ 0.01 9.99E−22 2.82 (0.98–8.14) 0.05
‘hsa-miR-18b-5p’ 0.009 1.49E−27 2.54 (0.97–6.69) 0.06
‘hsa-miR-324-5p’ 0.03 1.09E−21 2.62 (0.85–8) 0.09
‘hsa-miR-96-5p’ 0.018 1.40E−22 2.19 (0.87–5.53) 0.1
Cancer-speciﬁc survival
‘hsa-miR-139-3p’ 0.004 1.08E−25 0.33 (0.12–0.87) 0.02
‘hsa-miR-21-5p’ 0.04 4.29E−05 2.41 (1.1–5.53) 0.04
‘hsa-miR-21-3p’ 0.03 5.20E−08 2.17 (0.98–4.83) 0.06
‘hsa-miR-17-3p’ 0.02 3.33E−07 2.1 (0.91–4.71) 0.08
t-Test and multivariable analyses of prognostic microRNAs.
aThe analyses were carried out considering high versus low expression groups excluding the patients with an intermediate signal. Multivariable model adjusted
for primary tumor site (RFS, CSS), adjuvant therapy (RFS, CSS) and TP53 status (RFS).
KM, Kaplan–Meier; HR, hazard risk; CI, conﬁdence interval.
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In multivariable Cox proportional hazards regression model,
adjusting for other signiﬁcant prognostic indicators, we
determined that each of these miRNAs predicts RFS and/or CSS
independently from the other variables (Table 2 and
supplementary Table S4, available at Annals of Oncology online).
We next investigated whether these 12 and 4 miRNAs groups
(which will be indicated hereafter with the terms 12mG and
4mG) predict, respectively, RFS and CSS when they are
considered as signatures. We assigned a score to each patient
based on the expression levels of the 12mG or of the 4mG (see
supplementary Material, available at Annals of Oncology
online), and Kaplan–Meier analyses were carried out comparing
patients with positive and negative scores. As shown in
Figure 3A, patients with positive score for the 12mG showed
reduced RFS compared with patients with negative score.
Moreover, patients with positive score for the 4mG showed
reduced CSS compared with patients with negative score
(Figure 3B). When the 12mG and 4mG scores were tested in
multivariable analyses, we could assess that the identiﬁed groups
of miRNAs were able to predict outcome independently from
the other clinical variables (e.g. tumor site, adjuvant treatment
and TP53 status) (Figure 3A and B, bottom, and supplementary
Table S4, available at Annals of Oncology online). Of note,
adjusting for the 12mG score, TP53 status did not remain an
independent prognostic factor for RFS (supplementary
Table S4, available at Annals of Oncology online). Finally, the
association between miRNAs groups and outcome remained
signiﬁcant also in χ2 test (supplementary Table S5, available at
Annals of Oncology online).
discussion
The main ﬁnding of our study is that TP53mutations are
associated with the up- or down-regulation of speciﬁc miRNAs
in squamous cell carcinomas of the head and neck. Some of
these miRNAs are able to predict RFS and CSS. Of note, these
prognostic miRNAs are strong predictors of survival also when
considered as signatures.
The presence of a TP53mutation was previously associated
with decreased survival in HNSCC [9], as compared with wild-
type TP53. We detected single or multiple TP53 mutations in
58% of the analyzed tumors and this frequency is in line with
what recently reported [26].
We explored the possibility that TP53mutations are
associated with miRNA expression alteration in HNSCC. We
identiﬁed 49 miRNAs signiﬁcantly associated with TP53 status.
Interestingly, 5 of the 49 miRNAs discriminating wild-type and
mutant TP53 (miR-135b-5p, miR-18a-5p, miR-18b-5p, miR-
224-5p and miR-452-5p) were previously identiﬁed as expressed
at higher levels in mutant TP53 versus wild-type TP53 in a
similar study in breast cancer [23].
Figure 3. miRNAs expression predicts clinical outcome of HNSCC patients. (A and B) Kaplan–Meier analyses representing the correlation between the
expression of the groups of 12mG and 4mG and clinical outcome in the whole series of HNSCC patients. Kaplan–Meier analyses were carried out dividing the
patients in two subsets: patients with positive score versus patients with negative score according to the expression level of the groups of 12 (A) and 4 (B)
prognostic miRNAs. See supplementary Material, available at Annals of Oncology online, for score calculation details. The multivariable analyses relative to
cancer-speciﬁc survival (A) and recurrence-free survival (B) are shown at the bottom.
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We examined the expression levels of TP53-associated
miRNAs in tumor versus normal samples separately on the
TP53-mutated and wild-type groups. Of note, only in the TP53-
mutated group, all miRNAs except one were also deregulated in
the tumor tissue compared with the normal counterparts.
Several of these miRNAs have been previously reported to be
altered in head and neck tumors with same kind of deregulation
(up- or down-regulation) [27]. Of note, when we evaluated the
group of miRNAs predicting RFS (12 miRNAs) or CSS (4
miRNAs) in multivariable analyses we observed that they
predict outcome independently from the other relevant clinical
variables (e.g. TP53 status, tumor site and adjuvant therapy). On
the contrary TP53mutations are no more signiﬁcant adjusting
for miRNAs signatures expression, indicating that miRNAs
overcome TP53 status in recurrence prediction.
Some of the TP53-associated miRNAs predicting clinical
outcome was also previously reported to be prognostic in
HNSCC, as miR-151a-3p, miR-324-5p and miR-21 [28, 29].
In conclusion, we have demonstrated that the expression of
signatures of TP53mutation-associated miRNAs, composed of
12 and 4 miRNAs, predicts, respectively, the risk of local
recurrence insurgence and poor outcome, independently from
other relevant prognostic indicators.
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